The allocation and use of Developmental Funds has been managed centrally. Developmental Funds at UPCI have been utilized in two w/ays: 1) New Investigator and Program Support, to enhance research areas that have been identified in the strategic planning process as high priority for development and expansion;and 2) Pilot funding of UPCI member projects deemed by an internal advisory committee to be the most meritorious scientifically and likely to facilitate interactions among program members or to lead to subsequent success in obtaining major external funding. These developmental funds have been extremely helpful to vigorously promote the high priority goals of UPCI. The review of this funding category at the last competitive renewal ofthe CCSG rated it as having Excellent to Outstanding merit. Following the same approach that has been quite successful to date, it is proposed that the majority of funds being requested will be utilized to support recruitment in high priority areas for ongoing development and expansion. To a lesser extent, Developmental Funds will be used to fund pilot projects that explore innovative ideas and develop new collaborations as well as to enhance the capability of shared facilities to a lesser extent. We are requesting $278,079 towards faculty development, $200,000 for pilot projects and $100,000 for shared facilities development.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-25
Application #
8519319
Study Section
Special Emphasis Panel (ZCA1-RTRB-L)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
25
Fiscal Year
2013
Total Cost
$476,733
Indirect Cost
$69,738
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Krishnamurthy, Anuradha; Dasari, Arvind; Noonan, Anne M et al. (2018) Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. Cancer Res 78:5398-5407
Santos, Patricia M; Butterfield, Lisa H (2018) Next Steps for Immune Checkpoints in Hepatocellular Carcinoma. Gastroenterology 155:1684-1686
Gao, Ying; Tan, Jun; Jin, Jingyi et al. (2018) SIRT6 facilitates directional telomere movement upon oxidative damage. Sci Rep 8:5407
Lontos, Konstantinos; Tsagianni, Anastasia; Yuan, Jian-Min et al. (2018) Location matters in early stage nodal diffuse large B-cell lymphoma. Leuk Lymphoma :1-4
Toptan, Tuna; Abere, Bizunesh; Nalesnik, Michael A et al. (2018) Circular DNA tumor viruses make circular RNAs. Proc Natl Acad Sci U S A 115:E8737-E8745
Liu, Zuqiang; Ge, Yan; Wang, Haiyan et al. (2018) Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2. Nat Commun 9:4682
Vendetti, Frank P; Karukonda, Pooja; Clump, David A et al. (2018) ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation. J Clin Invest 128:3926-3940
Correa, Andres F; Toussi, Amir; Amin, Milon et al. (2018) Small Renal Masses in Close Proximity to the Collecting System and Renal Sinus Are Enriched for Malignancy and High Fuhrman Grade and Should Be Considered for Early Intervention. Clin Genitourin Cancer 16:e729-e733
Wang, Yi-Jun; Fletcher, Rochelle; Yu, Jian et al. (2018) Immunogenic effects of chemotherapy-induced tumor cell death. Genes Dis 5:194-203
Bakkenist, Christopher J; Lee, James J; Schmitz, John C (2018) ATM Is Required for the Repair of Oxaliplatin-Induced DNA Damage in Colorectal Cancer. Clin Colorectal Cancer 17:255-257

Showing the most recent 10 out of 1187 publications